ArticleThe journal of prevention of Alzheimer's disease2024
Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States.
Article in The journal of prevention of Alzheimer's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Utilization and Lifetime Costs of Formal Care for Alzheimer's Disease Dementia in Sweden.PharmacoEconomics · 2026Article
- Increase in healthcare utilization and Medicare payment with progression of preclinical Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2026Article
- The relationship between oral frailty and cognitive function in elderly patients with chronic diseases: the chain-mediated effect of nutrition status and the inflammatory marker CRP.BMC geriatrics · 2025Article
- Alzheimer's Disease in Illinois: Analyzing Disparities and Projected Trends.Geriatrics (Basel, Switzerland) · 2025Review
- Healthcare Spending Before and After Mild Cognitive Impairment Diagnosis: Evidence from the NHIS-NHID in Korea.Healthcare (Basel, Switzerland) · 2025Article
- Real-world health care costs and resource utilization associated with mild cognitive impairment in the United States: A retrospective cohort study of commercial and Medicare data.Journal of managed care & specialty pharmacy · 2025Article
- The economic burden of subjective cognitive decline, mild cognitive impairment and Alzheimer's dementia: excess costs and associated clinical and risk factors.Alzheimer's research & therapy · 2025Article
- [Cognitive impairment in hearing impaired patients compared to normal hearing patients].Revista medica del Instituto Mexicano del Seguro Social · 2025Observational
- Molecular pathogenesis of Alzheimer's disease onset in a mouse model: effects of cannabidiol treatment.Frontiers in neuroscience · 2025Article
- Cognitive Function and the Consumption of Probiotic Foods: A National Health and Nutrition Examination Survey Study.Nutrients · 2024Article
- Prevalence and Correlates of Mild Cognitive Impairment in Older Outpatients: A Cross-Sectional Study.Inquiry : a journal of medical care organization, provision and financingArticle
- Risk prediction of mild cognitive impairment using electronic health record data.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLimited evidence exists on the economic burden of individuals who progress from mild cognitive impairment (MCI) to Alzheimer disease and related dementia disorders (ADRD).
objectivesTo assess the all-cause health care resource utilization and costs for individuals who develop ADRD following an MCI diagnosis compared to those with stable MCI.
designThis was a retrospective cohort study from January 01, 2014, to December 31, 2019.
settingThe Merative MarketScan Commercial and Medicare Databases were used.
participantsIndividuals were included if they: (1) were aged 50 years or older; (2) had ≥1 claim with an MCI diagnosis based on the International Classification of Diseases, Ninth Revision (ICD-9) code of 331.83 or the Tenth Revision (ICD-10) code of G31.84; and had continuous enrollment. Individuals were excluded if they had a diagnosis of Parkinson's disease or ADRD or prescription of ADRD medication. MEASUREMENTS: Outcomes included all-cause utilization and costs per patient per year in the first 12 months following MCI diagnosis, in total and by care setting: inpatient admissions, emergency department (ED) visits, outpatient visits, and pharmacy claims.
resultsOut of the total of 5185 included individuals, 1962 (37.8%) progressed to ADRD (MCI-to-ADRD subgroup) and 3223 (62.2%) did not (Stable MCI subgroup). Adjusted all-cause utilization was higher for all care settings in the MCI-to-ADRD subgroup compared with the Stable MCI subgroup. Adjusted all-cause mean total costs ($34 599 vs $24 541; mean ratio [MR], 1.41 [95% CI, 1.31-1.51]; P<.001), inpatient costs ($47 463 vs $38 004; MR, 1.25 [95% CI, 1.08-1.44]; P=.002), ED costs ($4875 vs $3863; MR, 1.26 [95% CI, 1.11-1.43]; P<.001), and outpatient costs ($16 652 vs $13 015; MR, 1.28 [95% CI, 1.20-1.37]; P<.001) were all significantly higher for the MCI-to-ADRD subgroup compared with the Stable MCI subgroup.
conclusionsIndividuals who progressed from MCI to ADRD had significantly higher health care costs than individuals with stable MCI. Early identification of MCI and delaying its progression is important to improve patient and economic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.